Leveraging Technology to Avoid Costly Clinical Trial Delays

Drug developers face great pressures to complete clinical trials on time and on budget, but challenges like patient recruitment, patient retention, and site selection can cause unexpected delays with significant economic consequences. This is particularly true in the area of rare disease drug development where patient populations are small and geographically dispersed. Arthur D. Little works with clinical trial sponsors to leverage technology and avoid these pitfalls. We spoke to Ben Enejo and Ben van der Schaaf, both partners in the life sciences practice of Arthur D. Little, about the challenges of rare disease drug development, how concerns about equity and diversity are adding to those challenges, and how the firm leverages technology to help its clients overcome the hurdles they face. 

‍